RxDoctor Payments Data

Jessica Malone, NP

Nurse Practitioner · Macon, GANPI 1659931277

Payments from drug & device makers

$3,922in general payments, 2019–2025

Across 148 payments — averaging $26.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$637
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$592
  • AstraZeneca$542
  • Abiomed$379
  • Novartis$354
  • Amgen$327
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,922100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,922 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$61,515
Medicare patients
486
Services billed
854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$64,578
EntrestoSacubitril/Valsartan38$32,747
FarxigaDapagliflozin Propanediol24$32,010
BrilintaTicagrelor43$28,714
XareltoRivaroxaban16$20,221
Repatha SureclickEvolocumab24$16,346
Praluent PenAlirocumab20$12,325
Ranolazine ErRanolazine21$1,929
Metoprolol Succinate115$1,452
ClopidogrelClopidogrel Bisulfate106$1,329
Rosuvastatin Calcium72$1,305
Prasugrel Hcl14$1,194
Nitroglycerin88$1,153
Atorvastatin Calcium88$1,124
Carvedilol103$957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$95$64,57867 claims
AstraZenecaFarxiga, Brilinta$542$60,72467 claims
NovartisEntresto$354$32,74738 claims
Johnson & JohnsonXarelto$637$20,22116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →